Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the European rheumatoid arthritis (RA) drug market will grow from $371 million in 2002 to more than $3 billion in 2012. According to a new Pharmacor study entitled Rheumatoid Arthritis, the majority of this growth will be driven by biologic agents.

"The European Union's publication of guidelines regarding the use of biologic agents, coupled with the ongoing accumulation of long-term safety data, will encourage physicians to prescribe currently available biologics more frequently," said Melissa Garland, analyst at Decision Resources. "From 2002 to 2012, European sales of biologic agents will increase by a dramatic 33% per year."

The study also finds that the Japanese RA market will experience similar dynamic growth, which will be fueled by the launches of two classes of drugs: biologic agents and selective cyclooxygenase-2 (COX-2) inhibitors.

"Infliximab will quickly become the top-selling biologic agent in Japan for two reasons: 1) infliximab was approved in July 2003 as the first biologic for the treatment of RA in Japan, and 2) Schering-Plough will market infliximab in conjunction with Tanabe, a Japanese company," continued Ms. Garland.

About Rheumatoid Arthritis

RA is a chronic inflammatory condition characterized by progressive join degradation. RA was long viewed as a relatively benign disease, in part because its onset occurs over weeks and months, but it is now established that the disease causes substantial destruction of the joints early in its course.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

HIV Drug Market to Grow to More Than $8 Billion by 2013

View Now